Objective
The rapidly increasing number of therapeutic antibodies and biosimilars
on the market requires corresponding tools for monitoring the concentration of
these drugs in preclinical and patient samples and for measurement of anti-drug
antibodies.
The poster will present the use of the HuCAL® technology for
fast development of fully human Fab and Ig anti-idiotypic antibodies binding
specifically and with high affinity to well-known drugs, such as adalimumab,
trastuzumab and cetuximab. Such antibodies are ideal for the development of bioanalytical
assays, such as PK, PD and ADA assays.
Antibody specificity can be driven to result in different binding
modes and properties – inhibitory, non-inhibitory and drug-target complex
binders – allowing for the development of assays that measure free drug, total
drug and bound drug exclusively. The development of these three different types
of antibodies will be described.
